Secondary Oral Vancomycin Prophylaxis and Clostridioides difficile Infection in Children and Young Adults With Cancer: A Retrospective Cohort Study
Authors:
- Isabela DeJohnIDIsabela DeJohn
- Chunyan LiuCLChunyan Liu
- Caitlin BrammerCBCaitlin Brammer
- Maryam MysorewalaMMMaryam Mysorewala
- Joshua D CourterJCJoshua D Courter
- Justin MarkhamJMJustin Markham
- Soumya JaiswalSJSoumya Jaiswal
- Grant PaulsenGPGrant Paulsen
- Lara Danziger-IsakovLDLara Danziger-Isakov
- William R OttoWOWilliam R Otto
Open Access
- 20 June 2026
- Vol. 13 (7)
Abstract
Secondary oral vancomycin prophylaxis has been reported to reduce rates of recurrent Clostridioides difficile infection (CDI) in adult patients, but there are limited data in pediatrics. This study sought to assess the impact of secondary oral vancomycin prophylaxis (OVP) during broad-spectrum antibiotic administration in reducing CDI in children and young adults with cancer. This was a retrospective study of children and young adults with cancer with primary CDI episode treated from 2017 to 2024. To determine the causal impact of secondary oral vancomycin prophylaxis during antibiotic administration to prevent CDI in the 6 months after the primary episode, propensity score matching and weighted generalized estimating equations were performed. The initial cohort included 163 patients who experienced primary CDI. After exclusions, 72 patients received 150 courses of broad-spectrum antibiotics within 6 months following their initial infection. Fifteen patients received 27 episodes of OVP. CDIs were not significantly decreased, occurring in 22 of 123 (17.9%) courses in patients who did not receive OVP and 2 of 27 (7.4%) in courses with prophylaxis. Propensity score matching resulted in 49 broad-spectrum antibiotic episodes from 19 patients, forming 11 matched sets. Receipt of OVP was significantly associated with reduced risk of CDI (adjusted odds ratio, 0.074 [95% confidence interval, .01–.54]). In this single-center retrospective study of children and young adults with cancer with primary CDI, receipt of OVP was significantly associated with reduced risk of CDI recurrence when receiving broad-spectrum antibiotic therapy. Given the small sample size and likely residual confounding, these findings should be considered hypothesis-generating pending confirmation in larger studies.Keywords
This publication has 23 references indexed in Scilit:
- Sensitivity Analysis in Observational Research: Introducing the E-ValueAnnals of Internal Medicine, 2017
- Development and Application of an Antibiotic Spectrum Index for Benchmarking Antibiotic Selection Patterns Across HospitalsInfection Control & Hospital Epidemiology, 2017
- Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile InfectionsAmerican Journal of Gastroenterology, 2016
- Short- and long-term effects of oral vancomycin on the human intestinal microbiotaJournal of Antimicrobial Chemotherapy, 2016
- Efficacy of Oral Vancomycin in Preventing RecurrentClostridium difficileInfection in Patients Treated With Systemic Antimicrobial Agents: Table 1.Clinical Infectious Diseases, 2016
- Use of Acid Suppression Medication is Associated With Risk forC. difficileInfection in Infants and Children: A Population-based StudyClinical Infectious Diseases, 2015
- Trends in Clostridium difficile Infection and Risk Factors for Hospital Acquisition of Clostridium difficile among Children with CancerThe Journal of Pediatrics, 2013
- Clostridium difficile Infection Among Children With CancerThe Pediatric Infectious Disease Journal, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile -Associated DiseaseAntimicrobial Agents and Chemotherapy, 2008